NICE says Bayer's Xarelto can compete with BI's Pradaxa in England and Wales
This article was originally published in Scrip
Executive Summary
NICE, the health technology appraisal institute for England and Wales, has given NHS prescribers the official green light to choose Bayer's warfarin replacement Xarelto (rivaroxaban) for stroke prevention in patients with atrial fibrillation. The drug will compete against Boehringer Ingelheim's blockbuster Pradaxa (dabigatran etexilate), although both manufacturers may have to overcome certain hurdles, such as prescriber concerns over anticoagulation levels and international normalized ratio (INR) monitoring, before either drug reaches its full market potential.
You may also be interested in...
Lack Of Industry Involvement In EU HTA Scoping Process Exacerbates ‘Unworkable’ Timelines
Scientific advice could help companies make up for the lack of involvement in scoping, but slots are in short supply.
German HTA Queries Polivy Benefits Amid Lack Of Evidence
Roche’s lymphoma drug Polivy could face pricing challenges in Germany as it undergoes a full benefit assessment.
Germany Confirms No Reimbursement Status For ‘Lifestyle’ Drug Wegovy
In Germany Novo Nordisk’s obesity drug Wegovy will remain excluded from reimbursement for obesity, unlike Rhythm’s Imcivree.